Chimerix (NASDAQ:CMRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Chimerix (NASDAQ:CMRX) in a report published on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently commented on CMRX. Wedbush reaffirmed a “neutral” rating and set a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. HC Wainwright reissued a “neutral” rating and issued a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Chimerix Stock Performance

Chimerix stock opened at $8.54 on Friday. Chimerix has a 52 week low of $0.75 and a 52 week high of $8.55. The stock has a market capitalization of $801.09 million, a P/E ratio of -9.09 and a beta of -0.17. The stock has a fifty day moving average of $8.51 and a 200-day moving average of $4.87.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. The firm had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.31 million. On average, research analysts forecast that Chimerix will post -0.99 earnings per share for the current year.

Insider Buying and Selling at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders sold 14,595 shares of company stock valued at $65,889. Company insiders own 13.10% of the company’s stock.

Institutional Trading of Chimerix

A number of hedge funds have recently bought and sold shares of the business. Deerfield Management Company L.P. Series C purchased a new position in shares of Chimerix in the fourth quarter valued at $13,124,000. Rosalind Advisors Inc. bought a new stake in shares of Chimerix in the 4th quarter valued at about $10,614,000. Alpine Associates Management Inc. bought a new stake in shares of Chimerix in the 1st quarter valued at about $23,676,000. Millennium Management LLC lifted its stake in shares of Chimerix by 6.8% in the 4th quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock valued at $8,900,000 after acquiring an additional 161,795 shares during the last quarter. Finally, Marshall Wace LLP raised its position in Chimerix by 1,318.5% during the 4th quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock valued at $7,705,000 after purchasing an additional 2,057,864 shares during the last quarter. 45.42% of the stock is currently owned by institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.